Aptus Pharma Ltd
Incorporated in 2010, Aptus Pharma Ltd is engaged in the business of marketing and distribution of finished pharmaceutical formulations.[1]
- Market Cap ₹ 317 Cr.
- Current Price ₹ 185
- High / Low ₹ 186 / 32.3
- Stock P/E 68.7
- Book Value ₹ 13.6
- Dividend Yield 0.00 %
- ROCE 30.0 %
- ROE 30.5 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company has a good return on equity (ROE) track record: 3 Years ROE 40.8%
Cons
- Stock is trading at 13.6 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 99.8 to 147 days.
- Working capital days have increased from 73.4 days to 117 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 13.90 | 17.81 | 24.56 | 46.57 | |
| 13.28 | 16.27 | 19.71 | 39.12 | |
| Operating Profit | 0.62 | 1.54 | 4.85 | 7.45 |
| OPM % | 4.46% | 8.65% | 19.75% | 16.00% |
| 0.00 | 0.03 | 0.08 | 0.13 | |
| Interest | 0.14 | 0.24 | 0.47 | 0.80 |
| Depreciation | 0.18 | 0.21 | 0.27 | 0.41 |
| Profit before tax | 0.30 | 1.12 | 4.19 | 6.37 |
| Tax % | 33.33% | 28.57% | 26.01% | 27.47% |
| 0.19 | 0.80 | 3.10 | 4.62 | |
| EPS in Rs | 2.38 | 10.00 | 2.48 | 2.69 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 50% |
| TTM: | 90% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 190% |
| TTM: | 49% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 41% |
| Last Year: | 30% |
Balance Sheet
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.30 | 0.30 | 5.00 | 6.86 |
| Reserves | 0.67 | 1.47 | 1.97 | 16.49 |
| 2.22 | 5.31 | 10.35 | 7.18 | |
| 3.02 | 2.95 | 4.60 | 13.00 | |
| Total Liabilities | 6.21 | 10.03 | 21.92 | 43.53 |
| 0.52 | 0.63 | 0.99 | 2.77 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| 5.69 | 9.40 | 20.93 | 40.76 | |
| Total Assets | 6.21 | 10.03 | 21.92 | 43.53 |
Cash Flows
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| -0.18 | -2.17 | -1.84 | -6.86 | |
| -0.35 | -0.30 | -0.54 | -6.37 | |
| 0.81 | 2.86 | 6.68 | 9.04 | |
| Net Cash Flow | 0.28 | 0.38 | 4.30 | -4.19 |
| Free Cash Flow | -0.53 | -2.50 | -2.46 | -9.05 |
| CFO/OP | -10% | -119% | -15% | -76% |
Ratios
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 63.02 | 68.66 | 83.82 | 147.03 |
| Inventory Days | 176.00 | 183.57 | 285.06 | 231.78 |
| Days Payable | 104.07 | 72.25 | 52.89 | 139.20 |
| Cash Conversion Cycle | 134.95 | 179.97 | 315.98 | 239.61 |
| Working Capital Days | 51.99 | 67.02 | 36.41 | 116.78 |
| ROCE % | 26.48% | 38.20% | 29.97% |
Documents
Announcements
-
Disclosure As Per Regulation 7(2) Of SEBI (PIT) Regulations, 2015
1d - Promoter-group members reported off-market inter-se transfers of Aptus Pharma shares on 11–13 May 2026.
-
Disclosures under Reg. 29(1) / 29(2) of SEBI (SAST) Regulations, 2011
14 May - The the disclosure under Regulation 29(1) / 29(2) of SEBI (SAST) Regulations, 2011 for Kripaliben Mayank Thakker
-
Disclosures under Reg. 29(1) / 29(2) of SEBI (SAST) Regulations, 2011
14 May - The the disclosure under Regulation 29(1) / 29(2) of SEBI (SAST) Regulations, 2011 for Kunjal Unadkat
-
Disclosures under Reg. 29(1) / 29(2) of SEBI (SAST) Regulations, 2011
14 May - The the disclosure under Regulation 29(1) / 29(2) of SEBI (SAST) Regulations, 2011 for Riddhish Natwarlal Tanna
-
Disclosures under Reg. 29(1) / 29(2) of SEBI (SAST) Regulations, 2011
14 May - The the disclosure under Regulation 29(1) / 29(2) of SEBI (SAST) Regulations, 2011 for Milly Chetan Lalseta
Annual reports
No data available.
Concalls
-
Feb 2026TranscriptAI SummaryPPT
Business Profile[1]
Aptus Pharma Limited is a Gujarat-based marketer and distributor of pharmaceutical formulations, operating in an asset-light model through contract manufacturing partners. It offers a diverse portfolio of 194 products across multiple therapeutic categories.